J&J expands cancer portfolio with $3.05 billion Halda buy

Johnson & Johnson said on Monday it would buy privately held Halda Therapeutics for $3.05 billion in cash, aiming to expand ...
BioSpace

J&J, Aiming for $50B in Cancer Sales, Buys Halda for $3B in Cash

Halda Therapeutics is developing oral assets for prostate and lung cancer. The deal comes after Johnson & Johnson set an ...
Fierce Biotech

J&J buys into Halda's cell death tech with $3B acquisition, beefing up prostate cancer pipeline

Johnson & Johnson is paying $3.05 billion to acquire Halda Therapeutics, obtaining a novel cell death platform while ...
NJBIZ

J&J to acquire Connecticut biotech in $3.05B oncology deal

J&J will acquire Halda Therapeutics in a $3.05B deal, adding prostate cancer therapy HLD-0915 and expanding its oncology ...
GEN - Genetic Engineering and Biotechnology News

J&J Expands Cancer Pipeline with $3B Halda Acquisition

Johnson & Johnson has agreed to acquire Halda Therapeutics for $3.05 billion cash, in a deal designed to expand the buyer’s cancer pipeline with Halda’s precision oncology candidates, led by a ...
BioPharma Dive

J&J adds to pharma’s M&A spree with $3B buyout of startup Halda

The deal gives J&J access to a pipeline of drugs designed to “hold and kill” tumors, led by a prostate cancer medicine that’s ...

Vida Ventures Marks Fourth Major Portfolio Acquisition in 2025, Capping a Record-Setting Year for Its Science-Led, Discipline-Driven Strategy

Vida Ventures ("Vida"), a next-generation life sciences venture firm, today announced its fourth major Vida portfolio ...